We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add AngioDynamics to Your Portfolio Now
Read MoreHide Full Article
AngioDynamics, Inc. (ANGO - Free Report) is likely to gain from a series of lucrative acquisitions and a robust product portfolio.
In the past three months, shares of AngioDynamics have gained 14.6% compared with the industry’s growth of 14%.
With a market capitalization of $441 million, the company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. Its devices are generally utilized in minimally invasive, image-guided procedures. The company has a trailing four-quarter earnings surprise of 111.7%, on average.
Let’s delve deeper into the factors that substantiate AngioDynamics’ Zacks Rank #1 (Strong Buy) at present.
Broad Product Line: AngioDynamics’ product lines include ablation and fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, and venous products.
The company continues to enjoy healthy demand for its coveted NanoKnife system for treating tumors. On the R&D front, the company continues to focus investments on its three key technologies, AngioVac, Auryon and NanoKnife, while working on ways to improve the profitability of its other products. For fiscal 2021, the company now anticipates R&D expenses between $35 million and $40 million. The company continued to see solid customer interest in the recent launches of its NanoKnife and AngioVac through the fiscal first quarter.
The company is on track to deliver two newAngioVac products in calendar year of 2021. During the fiscal first quarter, the company saw continued strength from its AngioVac platform. The company’s total VIT business grew 3.3% year over year, driven by AngioVac sales growth of 46% from the prior-year quarter.
The company also continues to progress with the Auryon technology. Management is currently anticipating Auryon to generate $7 million to $10 million in revenues in fiscal 2021.In the fiscal first quarter, the company’s VIT business raked in $1.1 million in sales from its Auryon platform.
In September 2020, the company launched the AuryonAtherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease, which includes Critical Limb Ischemia and In-Stent Restenosis. Laser atherectomy procedures with AURYON laser have continued gaining traction along with other procedures and are still very early in the ramp stage.
FDA Approval for DIRECT Study: Earlier, the company announced that it has received an approval from the FDA to initiate a clinical study for treating stage III pancreatic cancer. The approval is for an investigational device exemption (IDE) application for NanoKnife Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT).
The company’s PATHFINDER and DIRECT studies continue to remain primary focus, with activity in these studies continuing to improve through the fiscal first quarter, despite a temporary halt. By the end of the first fiscal quarter, 23 DIRECT study sites secured IRB approval as the company added two additional sites.
Which Way Are Estimates Headed?
For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $281 million, suggesting an improvement of 6.4% from the year-ago figure. For adjusted earnings, the same stands at a cent, indicating a decline of 88.9% from the prior year.
Other Key Picks
A few other top-ranked stocks from the broader medical space include Boston Scientific (BSX - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific (TMO - Free Report) .
DaVita’s long-term earnings growth rate is estimated at 11.9%. The company presently carries a Zacks Rank #1.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Here's Why You Should Add AngioDynamics to Your Portfolio Now
AngioDynamics, Inc. (ANGO - Free Report) is likely to gain from a series of lucrative acquisitions and a robust product portfolio.
In the past three months, shares of AngioDynamics have gained 14.6% compared with the industry’s growth of 14%.
With a market capitalization of $441 million, the company designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. Its devices are generally utilized in minimally invasive, image-guided procedures. The company has a trailing four-quarter earnings surprise of 111.7%, on average.
Let’s delve deeper into the factors that substantiate AngioDynamics’ Zacks Rank #1 (Strong Buy) at present.
Broad Product Line: AngioDynamics’ product lines include ablation and fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, and venous products.
The company continues to enjoy healthy demand for its coveted NanoKnife system for treating tumors. On the R&D front, the company continues to focus investments on its three key technologies, AngioVac, Auryon and NanoKnife, while working on ways to improve the profitability of its other products. For fiscal 2021, the company now anticipates R&D expenses between $35 million and $40 million. The company continued to see solid customer interest in the recent launches of its NanoKnife and AngioVac through the fiscal first quarter.
The company is on track to deliver two newAngioVac products in calendar year of 2021. During the fiscal first quarter, the company saw continued strength from its AngioVac platform. The company’s total VIT business grew 3.3% year over year, driven by AngioVac sales growth of 46% from the prior-year quarter.
The company also continues to progress with the Auryon technology. Management is currently anticipating Auryon to generate $7 million to $10 million in revenues in fiscal 2021.In the fiscal first quarter, the company’s VIT business raked in $1.1 million in sales from its Auryon platform.
In September 2020, the company launched the AuryonAtherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease, which includes Critical Limb Ischemia and In-Stent Restenosis. Laser atherectomy procedures with AURYON laser have continued gaining traction along with other procedures and are still very early in the ramp stage.
FDA Approval for DIRECT Study: Earlier, the company announced that it has received an approval from the FDA to initiate a clinical study for treating stage III pancreatic cancer. The approval is for an investigational device exemption (IDE) application for NanoKnife Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT).
The company’s PATHFINDER and DIRECT studies continue to remain primary focus, with activity in these studies continuing to improve through the fiscal first quarter, despite a temporary halt. By the end of the first fiscal quarter, 23 DIRECT study sites secured IRB approval as the company added two additional sites.
Which Way Are Estimates Headed?
For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $281 million, suggesting an improvement of 6.4% from the year-ago figure. For adjusted earnings, the same stands at a cent, indicating a decline of 88.9% from the prior year.
Other Key Picks
A few other top-ranked stocks from the broader medical space include Boston Scientific (BSX - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific (TMO - Free Report) .
Boston Scientific’s long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s long-term earnings growth rate is estimated at 11.9%. The company presently carries a Zacks Rank #1.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>